GlassScriptPhysician profile
Brandon Mikolich
NPI 1215102421
$20,438.57
in general payments reported to CMS, 2019-2025
40 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $655 · 2021: $1,434 · 2022: $2,953 · 2023: $1,261 · 2024: $1,486 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,271 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,270.97 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12,585.63 | 2019-2025 | Lifevest |
| Abbott Laboratories | $1,300.11 | 2019-2025 | Cardiomems, Aveir, Perclose Prostyle |
| Novartis Pharmaceuticals Corporation | $899.13 | 2019-2025 | |
| Amgen INC. | $829.42 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $787.68 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $734.83 | 2019-2025 | Farxiga, Lokelma, Wainua |
| E.R. Squibb & Sons, L.L.C. | $475.06 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $321.31 | 2019-2023 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.52 | 2019-2025 | Jardiance |
| Pfizer INC. | $253.28 | 2019-2025 | |
| Novo Nordisk INC | $227.90 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Sanofi-Aventis U.S. LLC | $218.23 | 2019-2024 | |
| Amarin Pharma, INC. | $195.75 | 2020-2023 | |
| Medtronic, INC. | $183.94 | 2021-2025 | Linq II, Corevalve Evolut R, Flexcath Advance |
| Kiniksa Pharmaceuticals, LTD. | $148.07 | 2021-2023 | Arcalyst |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $138.81 | 2023-2025 | |
| Edwards Lifesciences Corporation | $121.11 | 2021-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $102.44 | 2021-2025 | Verquvo, Capvaxive |
| Kiniksa Pharmaceuticals International, Plc | $85.32 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $55.89 | 2020-2025 | Nexletol |
| Recor Medical INC | $53.98 | 2025 | Paradise Ultrasound Renal Denervation System |
| Preventice Services, LLC | $53.47 | 2021 | |
| Shockwave Medical, INC | $43.00 | 2022-2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Hikma Pharmaceuticals USA | $34.56 | 2019 | |
| Philips North America LLC | $33.78 | 2025 | Coronary Other, Extended Holter |
| Lexicon Pharmaceuticals, INC. | $30.91 | 2024 | |
| Irhythm Technologies, INC. | $29.50 | 2024 | Zio Monitor, Zio Xt Patch |
| Scpharmaceuticals INC. | $28.84 | 2023-2025 | |
| Bridgebio Pharma, INC. | $24.51 | 2025 | Attruby |
| Baxter Healthcare | $20.57 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Acist Medical Systems, INC. | $18.48 | 2023 | |
| Ekos Corporation | $18.48 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.28 | 2024 | Opsumit |
| Alnylam Pharmaceuticals INC. | $15.91 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.44 | 2025 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $14.29 | 2019 | |
| Tactile Systems Technology INC | $14.21 | 2024 | Entre Plus, Flexitouch Plus |
| Regeneron Pharmaceuticals, INC. | $13.45 | 2019 | |
| Gilead Sciences, INC. | $12.93 | 2019 | |
| Astellas Pharma US INC | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Mikolich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.